Ai2 Limited is a Manchester University spin-out that has developed proprietary human protein-like substances which inhibit bacteria, fungi and viruses. Its products are intended to prevent infection on a wide range of medical devices such as urinary catheters and stents, and to be used in wound dressings and consumer products. The company is led by CEO Dr Jim McNairney. Ai2 will use the funds to continue to develop its technology. The article reports the company raised £1.75m in funding to support its development work. Backers named include managers of The North West Fund for Biomedical, SPARK Impact and MTI Firms (managers of UMIP Premier Fund). Ai2 Limited is a Manchester, UK–based developer of technology designed to prevent infection on a wide range of commonly used medical devices, including urinary catheters, stents and wound dressings. The company’s core platform targets microbial contamination across multiple device types and application areas. Recent financing is intended to progress the technology platform and to support alliances and partnerships to test specific applications such as contact lenses and wound dressings. Ai2 has previously received a £100,000 Grant for Research and Development (GRAND) in September 2009. The company’s founder and director, Dr. Curtis Dobson, said the funding will allow Ai2 to build on successes to date and implement and validate the technology in the hands of partners. The firm frames clinical infection as a serious problem and positions its platform as a potential lasting solution.

Total raised

$3M

Funding rounds

2

Latest round

Equity

Latest activity

Jan 2012